You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. 2-HOBA for Treatment of Pulmonary Hypertension

    SBC: MTI Biotech Incorporated            Topic: NHLBI

    PROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Programming Metabolically Fit TILs for Immunotherapy

    SBC: LIPO-IMMUNO TECH LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Zero Trust Methodology for Digital Modeling

    SBC: ISTARI, INC.            Topic: X22DOTCSO1

    At a high level, the major mission focus of this research is:  How can the DAF and broader DoD leverage Zero Trust methodology into digital model sharing and collaboration? The technical focus of this research is:  What is the best manner to link digital

    STTR Phase II 2023 Department of DefenseAir Force
  4. Affordable sialoglycans and associated reagents for expanded chemoenzymatic production

    SBC: Integrated Micro-Chromatography Systems, Inc.            Topic: 300

    Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Enabling Business Agility in DoD DevSecOps Software Development and Senior Management Environments

    SBC: AGILE TRANSFORMATION INC            Topic: AF21ATCSO1

    The current AgilityHealth measurement and performance platforms are used by over 70 commercial customers and government civilian agencies. Over 16,500 assessments with over 100,000 participants across 8,000 teams have been accomplished. Currently AgilityHealth is able to scale it’s solution across 23,000 individuals at a large enterprise while running assessments multiple times a year for every ...

    STTR Phase II 2022 Department of DefenseAir Force
  6. Development of peptide nucleic acid antibiotics

    SBC: NUBAD LLC            Topic: NIAID

    The world is rapidly heading towards a pre-1940’s scenario when it comes to fighting infectious disease. Antimicrobial resistance is a growing problem on a global scale, greatly hampering our abilities to quell worldwide epidemics such as influenza, SARS, COVID-19, tuberculosis and malaria, as well as the simple staphylococcus infection. Unless innovative strategies are developed to produce robu ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations

    SBC: ADVANCED SMART SYSTEMS AND EVALUATION TECHNOLOGIES, LLC            Topic: NIA

    Project Summary and Abstract Falls are the leading cause of death due to injury. Falls are so common that 30% of community dwelling older adults, and 50% of residents in Care Facilities will experience a fall in the coming year. The risk of falling substantially increases for those having Alzheimer’s disease and related dementias. The financial burden is significant with fall-related costs being ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. An Automated Patient Chart Error Detection System for Radiation Therapy

    SBC: Infondrian LLC            Topic: 101

    Project Summary/Abstract Every year, approximately 1,200 severe mistreatments happen in radiation therapy. Radiation therapy lawsuits rank in the top third of all medical specialties with an average of $313,000 per claim settled or litigated. The current method for detecting treatment errors is by a weekly patient chart check, where each treatment record is manually reviewed on a weekly basis. Thi ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government